Nuchtavorn N, Leanpolchareanchai J, Suntornsuk L, Macka M. Paper-based sol-gel thin films immobilized cytochrome P450 for enzyme activity measurement. Anal Chim Acta. 2020;1098:86-93 pubmed publisher

Gao L, Rutz L, Schrenk D. Structure-dependent hepato-cytotoxic potencies of selected pyrrolizidine alkaloids in primary rat hepatocyte culture. Food Chem Toxicol. 2020;135:110923 pubmed publisher

Nicoli E, Al Eisa N, Cluzeau C, Wassif C, Gray J, Burkert K, et al. Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. PLoS ONE. 2016;11:e0152007 pubmed publisher

Reed J, Dela Cruz A, Lomnicki S, Backes W. Inhibition of cytochrome P450 2B4 by environmentally persistent free radical-containing particulate matter. Biochem Pharmacol. 2015;95:126-32 pubmed publisher

De Oliveira A, Poça K, Totino P, Paumgartten F. Modulation of cytochrome P450 2A5 activity by lipopolysaccharide: low-dose effects and non-monotonic dose-response relationship. PLoS ONE. 2015;10:e0117842 pubmed publisher

Pethuan S, Duangkaew P, Sarapusit S, Srisook E, Rongnoparut P. Inhibition against mosquito cytochrome P450 enzymes by rhinacanthin-A, -B, and -C elicits synergism on cypermethrin cytotoxicity in Spodoptera frugiperda cells. J Med Entomol. 2012;49:993-1000 pubmed

Blanck O, Fowles J, Schorsch F, Pallen C, Espinasse Lormeau H, Schulte Koerne E, et al. Tertiary butyl alcohol in drinking water induces phase I and II liver enzymes with consequent effects on thyroid hormone homeostasis in the B6C3F1 female mouse. J Appl Toxicol. 2010;30:125-32 pubmed publisher

Garmire L, Garmire D, Hunt C. An in silico transwell device for the study of drug transport and drug-drug interactions. Pharm Res. 2007;24:2171-86 pubmed

Sun L, Chen C, Waxman D, Liu H, Halpert J, Kumar S. Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide. Arch Biochem Biophys. 2007;458:167-74 pubmed

Kashiwada S, Hinton D, Kullman S. Functional characterization of medaka CYP3A38 and CYP3A40: kinetics and catalysis by expression in a recombinant baculovirus system. Comp Biochem Physiol C Toxicol Pharmacol. 2005;141:338-48 pubmed

Scott E, Liu H, Qun He Y, Li W, Halpert J. Mutagenesis and molecular dynamics suggest structural and functional roles for residues in the N-terminal portion of the cytochrome P450 2B1 I helix. Arch Biochem Biophys. 2004;423:266-76 pubmed

Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues A, et al. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001;29:368-74 pubmed

Rolph C, Roberts P, Taylor S. Phospholipase-induced modulation of rat liver mixed-function oxidase activity. Biochem Soc Trans. 1999;27:371-4 pubmed

Renauld A, Melancon M, Sordillo L. Identification of in vitro cytochrome P450 modulators to detect induction by prototype inducers in the mallard duckling (Anas platyrhynchos). Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1999;122:273-81 pubmed

Beebe L, Roberts E, Fornwald L, Hollenberg P, Alworth W. Mechanism-based inhibition of mouse P4502b-10 by selected arylalkynes. Biochem Pharmacol. 1996;52:1507-13 pubmed

He Y, Szklarz G, Halpert J. Interconversion of the androstenedione hydroxylase specificities of cytochromes P450 2B4 and 2B5 upon simultaneous site-directed mutagenesis of four key substrate recognition residues. Arch Biochem Biophys. 1996;335:152-60 pubmed

Klekotka P, Halpert J. Benzyloxyresorufin as a specific substrate for the major phenobarbital-inducible dog liver cytochrome P450 (P4502B11). Drug Metab Dispos. 1995;23:1434-5 pubmed

Verschoyle R, Dinsdale D, Wolf C. Inhibition and induction of cytochrome P450 isoenzymes in rat lung. J Pharmacol Exp Ther. 1993;265:386-91 pubmed

Armstrong S, Renton K. Hepatic cytochrome P450 and related drug biotransformation during an outbreak of mouse hepatitis virus in a colony of Swiss BALB/c mice. Can J Physiol Pharmacol. 1993;71:188-90 pubmed

Nerurkar P, Park S, Thomas P, Nims R, Lubet R. Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse. Biochem Pharmacol. 1993;46:933-43 pubmed

Nims R, McClain R, Manchand P, Belica P, Thomas P, Mellini D, et al. Comparative pharmacodynamics of hepatic cytochrome P450 2B induction by 5,5-diphenyl- and 5,5-diethyl-substituted barbiturates and hydantoins in the male F344/NCr rat. J Pharmacol Exp Ther. 1994;270:348-55 pubmed

Yang H, Lee Q, Rettie A, Juchau M. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol Pharmacol. 1994;46:922-8 pubmed

Burke M, Thompson S, Elcombe C, Halpert J, Haaparanta T, Mayer R. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol. 1985;34:3337-45 pubmed

Meehan R, Forrester L, Stevenson K, Hastie N, Buchmann A, Kunz H, et al. Regulation of phenobarbital-inducible cytochrome P-450s in rat and mouse liver following dexamethasone administration and hypophysectomy. Biochem J. 1988;254:789-97 pubmed

Perrin R, Minn A, Ghersi Egea J, Grassiot M, Siest G. Distribution of cytochrome P450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels. Biochem Pharmacol. 1990;40:2145-51 pubmed